Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo

European Journal of Nuclear Medicine

Volumn 25, Issue 5, 1998, Pages 481-490

  Reubi, J C ^a   Waser, B ^a   Schaer, J C ^a   Laederach, U ^a   Erion, J ^b   Srinivasan, A ^b   Schmidt, M A ^b   Bugaj, J E ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b MALLINCKRODT PHARMACEUTICALS   (United States)

Author keywords

@?Metal chelating ligands; Biodistribution; Cholecystokinin; Cholecystokinin B receptors; Octapeptide; Tumor targeting

Indexed keywords

CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ OCTAPEPTIDE DERIVATIVE; INDIUM 111; LIGAND; METAL CHELATE; PENTETIC ACID;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG STABILITY; DRUG UPTAKE; FEMALE; GASTROINTESTINAL TRACT; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; KIDNEY CLEARANCE; NONHUMAN; RAT; RECEPTOR AFFINITY; STOMACH MUCOSA;

ANIMALS; AUTORADIOGRAPHY; CHOLECYSTOKININ; FEMALE; HUMANS; INDIUM RADIOISOTOPES; NEOPLASMS; PENTETIC ACID; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CHOLECYSTOKININ; TISSUE DISTRIBUTION;

BINDING ENERGY; CHELATION; DISEASES; HISTOLOGY; LIGANDS; NUCLEAR MEDICINE; PEPTIDES; RATS;

AMETAL CHELATING LIGAND; BIODISTRIBUTIONS; CHELATING LIGANDS; CHOLECYSTOKININ; CHOLECYSTOKININ-B RECEPTOR; HUMAN TUMORS; IN-VITRO; IN-VIVO; OCTAPEPTIDE; TUMOR-TARGETING;

TUMORS;

EID: 0031746335     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050247     Document Type: Article

References (26)

1. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC. Somatostatin receptor scintigraphy. Nucl Med Annu 1995; 1995: 1-50.
2. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Pidlich J, Niederle B, Scheithauer W, Valent P. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994; 331: 1116-1121.
3. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 1995; 36: 1825-1835.
4. Fischman AJ, Babich JW, Strauss HW. A ticket to ride: peptide radiopharmaceuticals. J Nucl Med 1993; 34: 2253-2263.
5. Reubi JC, Waser B, Läderach U, Stettler C, Friess H, Halter F, Schmassmann A. Localization of cholecystokinin A and cholecystokinin B/gastrin receptors in the human stomach and gallbladder. Gastroenterology 1997; 112: 1197-1205.
6. Reubi JC, Waser B. Unexpected high incidence of cholecystokinin B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer 1996; 67: 644-647.
7. Reubi JC, Schaer JC, Waser B. Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997; 57: 1377-1386.
8. Atherton E, Sheppard RC. Fluorenylmethoxycarbonyl-poly-amide solid phase peptide synthesis. General principles and development. Oxford: Information Press, 1989.
9. Srinivasan A, Schmidt MA. Tri-t-butyl DTPA: a versatile synthon for the incorporation of DTPA by solid phase. American Peptide Symposium 1997. Nashville, Tennessee: Abstract P110.
10. Kates SA, Daniels SB, Albericio F. Automated allyl cleavage for continuous flow synthesis of cyclic and branched peptides. Anal Biochem 1993; 212: 303-310.
11. Mishra AK, Draillard K, Faivre-Chauvet A, Gestin JF, Curtet C, Chatal J. A convenient novel approach for the synthesis of ployaza macrocyclic bifunctional chelating agents. Tetrahedron Letters 1996; 37: 7515-7518.
12. Reubi JC, Kvols LK, Waser B, Nagorney D, Heitz PU. Charboneau JW, Reading CC, Moertel C. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990; 50: 5969-5977.
13. Wank SA. Cholecystokinin receptors. Am J Physiol 1995; 269: G628-G646.
14. 1)-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci 1991; 49: 1583-1591.
15. Pierson ME, Comstock JM, Simmons RD, Kaiser F, Julien R, Zongrone J, Rosamond JD. Synthesis and biological evaluation of potent, selective, hexapeptide CCK-A agonist anorectic agents. J Med Chem 1997; 40: 4302-4307.
16. Reeve JR, Eysselein V, Solomon TE, Go VLW, eds. Cholecystokinin. Ann NY Acad Sci 1994: Vol. 713.
17. 1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 1991; 49: 1593-1601.
18. Haldemann AR, Rösler H, Barth A, Waser B, Geiger L, Godoy N, Markwalder RV, Seiler RW, Sulzer M, Reubi JC. Somatostatin receptor scintigraphy in patients with CNS tumors: the role of blood brain barrier permeability. J Nucl Med 1995; 36: 403-410.
19. Jensen RT. CCK-B/gastrin receptor antagonists: recent advances and potential uses in gastric secretory disorders. Yale J Biol Med 1996; 69: 245-259.
20. Nouel D, Faure M, St. Pierre J, Alonso R, Quirion R, Beaudet A. Differential binding profile and internalization process of neurotensin via neuronal and glial receptors. J Neurosci 1997; 17: 1795-1803.
21. Clerc P, Dufresne M, Saillan C, Chastre E, André T, Escrieut C, Kennedy K, Vaysse N, Gespach C, Fourmy D. Differential expression of the CCK-A and CCK-B/gastrin receptor genes in human cancers of the esophagus, stomach and colon. Int J Cancer 1997; 72: 931-936.
22. Weinberg DS, Ruggeri B, Barber MT, Biswas S, Miknyocki S, Waldnian SA. Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma. J Clin Invest 1997; 100: 597-603.
23. Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, Roche A, Travagli JP, Parmentier C. Comparison of octreotide seintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996; 37: 912-916.
24. Reubi JC. Relevance of somatostatin receptors and other peptide receptors in pathology. Endocr Path 1997; 8: 11-20.
25. Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, Heppeler A, Mueller-Brand J, Maecke HR. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997; 24: 792-795.
26. Stolz B, Smith-Jones P, Weckhecker G, Albert R, Knecht H, Haller R, Tolcsvai L, Hofmann G, Pollehn K, Bruns C. Radiotherapy with yttrium-90 labeled DOTA-Tyr3-octreotide in tumor bearing rodents. J Nucl Med 1997; 38 [Suppl. to (5)]: 18P.